- Home
- AQST vs EDIT Comparison
AQST vs EDIT Comparison
Compare AQST & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AQST | EDIT |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.4M | 432.8M |
| IPO Year | 2007 | 2016 |
Fundamental Metrics
Financial Performance| Metric | AQST | EDIT |
|---|---|---|
| Price | $4.67 | $2.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $9.00 | $5.30 |
| AVG Volume (30 Days) | ★ 2.7M | 2.5M |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $67,430,000.00 | $31,937,000.00 |
| Revenue This Year | $10.08 | N/A |
| Revenue Next Year | $49.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 0.77 | ★ 132.64 |
| 52 Week Low | $2.94 | $1.66 |
| 52 Week High | $7.55 | $4.54 |
Technical Indicators
Market Signals| Indicator | AQST | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 51.60 | 41.50 |
| Support Level | $4.03 | $2.43 |
| Resistance Level | $5.10 | $2.73 |
| Average True Range (ATR) | 0.23 | 0.17 |
| MACD | -0.08 | -0.06 |
| Stochastic Oscillator | 23.73 | 8.54 |
Price Performance
Historical ComparisonAbout AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.